Endocrine Abstracts

Introduction: The actual prevalence of early carbohydrate metabolic disorders is associated with persistent hyperglycemia and can only be detected by targeted screening.

Objective: We examined 316 people aged 51.21(46.7;62.35) years, without DM.

Methods: We determined the 10-year risk of T2DM according to the Findrisc scale, anthropometric data, lipid profile, glycemia and HbA1c level, linear dimensions of preperitoneal and subcutenous fat by ultrasonography methods. HbA1c ≥ 6.5% was determined as persistent hyperglycemia marker.

Results: Among 316 examined, 13 patients had glycemia 5.6–6.9 mmol/l (4%), 11 patients had glycemia ≥ 7.0 mmol/l (3.6%), and 18 patients had HbA1c ≥ 6.5% (5.7%). According to Findrisc scale: below 7 points – 20%, 7–11 points – 48%, 12–14 points–13%, 15–20 points – 15%, more than 20 points – 4%. Among 60 people (≥15) after additional glycemia and oral glucose tolerance tests, T2DM was first diagnosed in 12 people (3.7%), prediabetes in 26 people (8.2%), of which impaired fasting glucose tolerance (IFG) – in 10, impaired glucose tolerance – in 16. Hyperglycemia development was significantly affected by an increase in the linear dimensions of preperitoneal fat (b = 0.62; Exp(b) = 1.86 (95% CI = 1.063.28); P = 0.03); increase of LDL and LDL-C (b = 1.21; Exp(b) = 3.36 (95% CI = 1.666.82) P = 0.001) and atherogenic index (AI) (b = 0.40; Exp (b) = 1.49 (95% CI = 1.131.20); P = 0.005). Increase of BMI and triglycerides increased the risk of persistent hyperglycemia at a steady tendency level. Statistically significant risk of developing persistent hyperglycemia was obtained with LDL-C > 1.6 mmol/l:RR<SUB>LDL-C ≥ 1,6[/SUB> = 5.51 (95% CI = 2.33 ÷ 13.05); AI > 2.55:RR<SUB>AI ≥ 2,55[/SUB> = 3.22 (95% CI = 1.36÷7.62). For the linear size of preperitoneal fat, the RR indices were at the level of steady tendecy RR<SUB>ППЖ ≥ 1,75[/SUB> = 2.22 (95% CI = 0.84 ÷ 5.83; 90% CI = 1.00 ÷ 4.99). It is noteworthy that the critical cutoff points of all indicators of the lipid profile lay in the range of reference values.

Conclusion: For T2DM screening, a Findrisc survey is justified, in spite of normal lipid profile values, ultrasonography of adipose tissue is required.